![Dirk Weber](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karriereverlauf von Dirk Weber
Ehemalige bekannte Positionen von Dirk Weber
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Aurealis Oy
![]() Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2010 | 01.06.2019 |
Gründer | 01.01.2010 | 01.06.2019 | |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2014 | - |
Gründer | 01.01.2014 | - |
Statistik
International
Finnland | 2 |
Schweiz | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Sektoral
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Aurealis Oy
![]() Aurealis Oy BiotechnologyHealth Technology Aurealis Oy operates as a biopharmaceutical company which develops treatment method that improves life for chronic inflammation and cancer sufferers. It develops a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. The company was founded by Dirk Weber and Thomas Wirth in 2010 and is headquartered in Kuopio, Finland. | Health Technology |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
- Börse
- Insiders
- Dirk Weber
- Erfahrung